PDF herunterladen
Am J Perinatol 2019; 36(S 02): S68-S73
DOI: 10.1055/s-0039-1691774
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Stem Cells for Extreme Prematurity

Bernard Thébaud
1   Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2   Department of Molecular Medicine, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
3   Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
4   Division of Neonatology, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Juni 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Regenerative medicine is a bourgeoning field promising to repair damaged organs and thus has created high hopes in neonatology to curb some of the complications due to extreme preterm birth. Extensive laboratory investigations over the past 15 years have tried to harness the regenerative potential of a variety of (stem) cell-based therapies. Most preclinical studies have focused on experimental neonatal lung and brain injury. These promising results lead to the initiation of phase I clinical trials for chronic lung disease of prematurity and severe intraventricular hemorrhage, two of the most devastating complications of extreme preterm birth. Despite this relative rapid clinical translation, major gaps persist in our understanding of the biology of these putative repair cells and our ability to predict the quality and thus the efficacy of the cell product. This review will provide a brief overview of the various cell-based therapies that have been investigated in experimental neonatal lung injury and the remaining challenges in utilizing these new, disruptive therapies to their full extend to realize the promise of regenerative medicine in neonatology.

Keywords

lung - injury - stem cells - regenerative medicine - preterm birth
 

  • References

  • 1 Stoll BJ, Hansen NI, Bell EF. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
    CrossrefPubMedGoogle Scholar
  • 2 Owen LS, Manley BJ, Davis PG, Doyle LW. The evolution of modern respiratory care for preterm infants. Lancet 2017; 389 (10079): 1649-1659
    CrossrefPubMedGoogle Scholar
  • 3 Thebaud B. Chronic lung disease in the neonate: past, present, and future. Neoreviews 2013; 14 (05) e252-e258
    CrossrefPubMedGoogle Scholar
  • 4 Collaco JM, McGrath-Morrow SA. Respiratory phenotypes for preterm infants, children, and adults: bronchopulmonary dysplasia and more. Ann Am Thorac Soc 2018; 15 (05) 530-538
    CrossrefPubMedGoogle Scholar
  • 5 Goss KN, Beshish AG, Barton GP. , et al. Early Pulmonary Vascular Disease in Young Adults Born Preterm. American Journal of Respiratory and Critical Care Medicine 2018; 198 (12) 1549-1558
    CrossrefPubMedGoogle Scholar
  • 6 Heinonen K, Eriksson JG, Lahti J. , et al. Late preterm birth and neurocognitive performance in late adulthood: a birth cohort study. Pediatrics 2015; 135 (04) e818-e825
    CrossrefPubMedGoogle Scholar
  • 7 Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 2013; 5 (179) 179ps7
    PubMedGoogle Scholar
  • 8 Fung ME, Thébaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014; 75 (1-1): 2-7
    CrossrefPubMedGoogle Scholar
  • 9 Willis GR, Fernandez-Gonzalez A, Anastas J. , et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med 2018; 197 (01) 104-116
    CrossrefPubMedGoogle Scholar
  • 10 Dominici M, Le Blanc K, Mueller I. , et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (04) 315-317
    CrossrefPubMedGoogle Scholar
  • 11 Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4 (05) 267-274
    PubMedGoogle Scholar
  • 12 Crisan M, Yap S, Casteilla L. , et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3 (03) 301-313
    CrossrefPubMedGoogle Scholar
  • 13 Popova AP, Bozyk PD, Bentley JK. , et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics 2010; 126 (05) e1127-e1133
    CrossrefPubMedGoogle Scholar
  • 14 Möbius MA, Freund D, Vadivel A. , et al. Oxygen disrupts human fetal lung mesenchymal cells. Implications for bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2019; 60 (05) 592-600
    CrossrefPubMedGoogle Scholar
  • 15 Collins JJP, Lithopoulos MA, Dos Santos CC. , et al. Impaired angiogenic supportive capacity and altered gene expression profile of resident CD146+ mesenchymal stromal cells isolated from hyperoxia-injured neonatal rat lungs. Stem Cells Dev 2018; 27 (16) 1109-1124
    CrossrefPubMedGoogle Scholar
  • 16 Aslam M, Baveja R, Liang OD. , et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009; 180 (11) 1122-1130
    CrossrefPubMedGoogle Scholar
  • 17 van Haaften T, Byrne R, Bonnet S. , et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009; 180 (11) 1131-1142
    CrossrefPubMedGoogle Scholar
  • 18 Pierro M, Ionescu L, Montemurro T. , et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013; 68 (05) 475-484
    CrossrefPubMedGoogle Scholar
  • 19 Chang YS, Choi SJ, Ahn SY. , et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One 2013; 8 (01) e52419
    CrossrefPubMedGoogle Scholar
  • 20 Augustine S, Avey MT, Harrison B. , et al. Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta-analysis of preclinical studies. Stem Cells Transl Med 2017; 6 (12) 2079-2093
    CrossrefPubMedGoogle Scholar
  • 21 Chang YS, Ahn SY, Yoo HS. , et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014; 164 (05) 966.e6-972.e6
    PubMedGoogle Scholar
  • 22 Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr 2017; 185: 49-54.e2
    CrossrefPubMedGoogle Scholar
  • 23 Álvarez-Fuente M, Arruza L, Lopez-Ortego P. , et al. Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile. Cytotherapy 2018; 20 (11) 1337-1344
    CrossrefPubMedGoogle Scholar
  • 24 Pierro M, Thébaud B, Soll R. Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 11: CD011932
    PubMedGoogle Scholar
  • 25 Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod 2007; 77 (03) 577-588
    CrossrefPubMedGoogle Scholar
  • 26 Vosdoganes P, Hodges RJ, Lim R. , et al. Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep. Am J Obstet Gynecol 2011; 205 (02) 156.e26-156.e33
    CrossrefPubMedGoogle Scholar
  • 27 Vosdoganes P, Lim R, Koulaeva E. , et al. Human amnion epithelial cells modulate hyperoxia-induced neonatal lung injury in mice. Cytotherapy 2013; 15 (08) 1021-1029
    CrossrefPubMedGoogle Scholar
  • 28 Vosdoganes P, Wallace EM, Chan ST, Acharya R, Moss TJ, Lim R. Human amnion epithelial cells repair established lung injury. Cell Transplant 2013; 22 (08) 1337-1349
    CrossrefPubMedGoogle Scholar
  • 29 Lim R, Malhotra A, Tan J. , et al. First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study. Stem Cells Transl Med 2018; 7 (09) 628-635
    CrossrefPubMedGoogle Scholar
  • 30 Baker EK, Malhotra A, Lim R. , et al. Human amnion cells for the prevention of bronchopulmonary dysplasia: a protocol for a phase I dose escalation study. BMJ Open 2019; 9 (02) e026265
    CrossrefPubMedGoogle Scholar
  • 31 Medina RJ, Barber CL, Sabatier F. , et al. Endothelial progenitors: a consensus statement on nomenclature. Stem Cells Transl Med 2017; 6 (05) 1316-1320
    CrossrefPubMedGoogle Scholar
  • 32 Ingram DA, Mead LE, Tanaka H. , et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104 (09) 2752-2760
    CrossrefPubMedGoogle Scholar
  • 33 Thébaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007; 175 (10) 978-985
    CrossrefPubMedGoogle Scholar
  • 34 Alphonse RS, Vadivel A, Zhong S. , et al. The isolation and culture of endothelial colony-forming cells from human and rat lungs. Nat Protoc 2015; 10 (11) 1697-1708
    CrossrefPubMedGoogle Scholar
  • 35 Alphonse RS, Vadivel A, Fung M. , et al. Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 2014; 129 (21) 2144-2157
    CrossrefPubMedGoogle Scholar
  • 36 Bertagnolli M, Nuyt AM, Thébaud B, Luu TM. Endothelial progenitor cells as prognostic markers of preterm birth-associated complications. Stem Cells Transl Med 2017; 6 (01) 7-13
    CrossrefPubMedGoogle Scholar
  • 37 Balasubramaniam V, Ryan SL, Seedorf GJ. , et al. Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol Lung Cell Mol Physiol 2010; 298 (03) L315-L323
    CrossrefPubMedGoogle Scholar
  • 38 Firsova AB, Bird AD, Abebe D, Ng J, Mollard R, Cole TJ. Fresh noncultured endothelial progenitor cells improve neonatal lung hyperoxia-induced alveolar injury. Stem Cells Transl Med 2017; 6 (12) 2094-2105
    CrossrefPubMedGoogle Scholar
  • 39 Baker CD, Seedorf GJ, Wisniewski BL. , et al. Endothelial colony-forming cell conditioned media promote angiogenesis in vitro and prevent pulmonary hypertension in experimental bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2013; 305 (01) L73-L81
    CrossrefPubMedGoogle Scholar
  • 40 Krause DS, Theise ND, Collector MI. , et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105 (03) 369-377
    CrossrefPubMedGoogle Scholar
  • 41 Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol 2005; 33 (04) 328-334
    CrossrefPubMedGoogle Scholar
  • 42 Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014; 507 (7491): 190-194
    PubMedGoogle Scholar
  • 43 Reddy R, Buckley S, Doerken M. , et al. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells. Am J Physiol Lung Cell Mol Physiol 2004; 286 (04) L658-L667
    CrossrefPubMedGoogle Scholar
  • 44 Chapman HA, Li X, Alexander JP. , et al. Integrin α6β4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest 2011; 121 (07) 2855-2862
    CrossrefPubMedGoogle Scholar
  • 45 Lin SE, Barrette AM, Chapin C. , et al. Expression of human carcinoembryonic antigen-related cell adhesion molecule 6 and alveolar progenitor cells in normal and injured lungs of transgenic mice. Physiol Rep 2015; 3 (12) e12657
    CrossrefPubMedGoogle Scholar
  • 46 Monz D, Tutdibi E, Mildau C. , et al. Human umbilical cord blood mononuclear cells in a double-hit model of bronchopulmonary dysplasia in neonatal mice. PLoS One 2013; 8 (09) e74740
    CrossrefPubMedGoogle Scholar
  • 47 Ahn SY, Chang YS, Sung DK. , et al. Cell type-dependent variation in paracrine potency determines therapeutic efficacy against neonatal hyperoxic lung injury. Cytotherapy 2015; 17 (08) 1025-1035
    CrossrefPubMedGoogle Scholar
  • 48 Moorefield EC, McKee EE, Solchaga L. , et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS One 2011; 6 (10) e26535
    CrossrefPubMedGoogle Scholar
  • 49 Carraro G, Perin L, Sedrakyan S. , et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 2008; 26 (11) 2902-2911
    CrossrefPubMedGoogle Scholar
  • 50 Grisafi D, Pozzobon M, Dedja A. , et al. Human amniotic fluid stem cells protect rat lungs exposed to moderate hyperoxia. Pediatr Pulmonol 2013; 48 (11) 1070-1080
    CrossrefPubMedGoogle Scholar
  • 51 Takahashi K, Tanabe K, Ohnuki M. , et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131 (05) 861-872
    CrossrefPubMedGoogle Scholar
  • 52 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126 (04) 663-676
    CrossrefPubMedGoogle Scholar
  • 53 Jacob A, Morley M, Hawkins F. , et al. Differentiation of human pluripotent stem cells into functional lung alveolar epithelial cells. Cell Stem Cell 2017; 21 (04) 472.e10-488.e10
    PubMedGoogle Scholar
  • 54 Shafa M, Ionescu LI, Vadivel A. , et al. Human induced pluripotent stem cell-derived lung progenitor and alveolar epithelial cells attenuate hyperoxia-induced lung injury. Cytotherapy 2018; 20 (01) 108-125
    CrossrefPubMedGoogle Scholar
  • 55 Liang Q, Monetti C, Shutova MV. , et al. Linking a cell-division gene and a suicide gene to define and improve cell therapy safety. Nature 2018; 563 (7733): 701-704
    PubMedGoogle Scholar
  • 56 Martin I, De Boer J, Sensebe L. ; MSC Committee of the International Society for Cellular Therapy. A relativity concept in mesenchymal stromal cell manufacturing. Cytotherapy 2016; 18 (05) 613-620
    CrossrefPubMedGoogle Scholar
  • 57 Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev 2012; 21 (15) 2789-2797
    CrossrefPubMedGoogle Scholar
  • 58 Sammour I, Somashekar S, Huang J. , et al. The effect of gender on mesenchymal stem cell (MSC) efficacy in neonatal hyperoxia-induced lung injury. PLoS One 2016; 11 (10) e0164269
    CrossrefPubMedGoogle Scholar
  • 59 Chen CM, Chou HC, Lin W, Tseng C. Surfactant effects on the viability and function of human mesenchymal stem cells: in vitro and in vivo assessment. Stem Cell Res Ther 2017; 8 (01) 180
    CrossrefPubMedGoogle Scholar
  • 60 Chinnadurai R, Copland IB, Garcia MA. , et al. Cryopreserved mesenchymal stromal cells are susceptible to t-cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells 2016; 34 (09) 2429-2442
    CrossrefPubMedGoogle Scholar
  • 61 Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol 2015; 77: 13-27
    CrossrefPubMedGoogle Scholar
  • 62 Bryan C, Sammour I, Guerra K. , et al. TNFα-stimulated protein 6 (TSG-6) reduces lung inflammation in an experimental model of bronchopulmonary dysplasia. Pediatr Res 2019; 85 (03) 390-397
    CrossrefPubMedGoogle Scholar
  • 63 Lal CV, Olave N, Travers C. , et al. Exosomal microRNA predicts and protects against severe bronchopulmonary dysplasia in extremely premature infants. JCI Insight 2018; 3 (05) 93994
    CrossrefPubMedGoogle Scholar
  • 64 Porzionato A, Zaramella P, Dedja A. , et al. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2019; 316 (01) L6-L19
    CrossrefPubMedGoogle Scholar
  • 65 Lesage F, Thébaud B. Nanotherapies for micropreemies: stem cells and the secretome in bronchopulmonary dysplasia. Semin Perinatol 2018; 42 (07) 453-458
    CrossrefPubMedGoogle Scholar
  • 66 Sucre JMS, Jetter CS, Loomans H. , et al. Successful establishment of primary type II alveolar epithelium with 3D organotypic coculture. Am J Respir Cell Mol Biol 2018; 59 (02) 158-166
    CrossrefPubMedGoogle Scholar
  • 67 Boregowda SV, Krishnappa V, Haga CL, Ortiz LA, Phinney DG. A clinical indications prediction scale based on TWIST1 for human mesenchymal stem cells. EBioMedicine 2015; 4: 62-73
    PubMedGoogle Scholar